Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic AlopeciaGlobeNewsWire • 12/04/25
Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 TranscriptSeeking Alpha • 11/22/25
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating ResultsGlobeNewsWire • 11/12/25
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025GlobeNewsWire • 10/29/25
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a TrialGlobeNewsWire • 10/15/25
Absci Corporation (ABSI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/09/25
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David GoldbergGlobeNewsWire • 08/25/25
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/12/25
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating ResultsGlobeNewsWire • 08/12/25
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology TargetGlobeNewsWire • 08/07/25
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 08/06/25
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025GlobeNewsWire • 07/30/25
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga • 07/25/25
Absci Reports Business Updates and First Quarter 2025 Financial and Operating ResultsGlobeNewsWire • 05/13/25